MEI Pharma Inc Total Assets
MEI Pharma Inc total assets. Based on the latest financial reports, MEI Pharma Inc (MEIP) holds total assets worth $18.29 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see MEI Pharma Inc market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of MEI Pharma Inc (2002–2025)
Total assets of MEI Pharma Inc from 2002 to 2025. This chart illustrates how MEI Pharma Inc's total assets have evolved over time, based on quarterly financial data. See latest MEI Pharma Inc stock price today for real-time trading data and today's change.
MEI Pharma Inc - Asset Composition Analysis
MEI Pharma Inc Total Assets Breakdown (June 2025)
MEI Pharma Inc total assets breakdown as of June 2025. MEI Pharma Inc's total assets of $18.29 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how MEI Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore MEI Pharma Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MEI Pharma Inc's current assets represent 100.0% of total assets in 2025, a decrease from 100.2% in 2002.
- Cash Position: Cash and equivalents constituted 98.5% of total assets in 2025, down from 99.8% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
MEI Pharma Inc Competitors by Total Assets
Key competitors of MEI Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
MEI Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.50 | 4.88 | 6.48 |
| Quick Ratio | 13.50 | 4.88 | 6.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $16.93 Million | $32.41 Million | $172.44 Million |
MEI Pharma Inc - Advanced Valuation Insights
This section examines the relationship between MEI Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.64 |
| Latest Market Cap to Assets Ratio | 5.51 |
| Asset Growth Rate (YoY) | -55.8% |
| Total Assets | $18.29 Million |
| Market Capitalization | $100.81 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values MEI Pharma Inc's assets at a significant premium (5.51x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: MEI Pharma Inc's assets decreased by 55.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for MEI Pharma Inc (2002–2025)
The table below shows the annual total assets of MEI Pharma Inc from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $18.29 Million | -55.81% |
| 2024-06-30 | $41.38 Million | -65.75% |
| 2023-06-30 | $120.81 Million | -32.07% |
| 2022-06-30 | $177.84 Million | +2.15% |
| 2021-06-30 | $174.10 Million | -16.99% |
| 2020-06-30 | $209.73 Million | +153.71% |
| 2019-06-30 | $82.66 Million | -21.02% |
| 2018-06-30 | $104.66 Million | +87.88% |
| 2017-06-30 | $55.70 Million | +18.11% |
| 2016-06-30 | $47.16 Million | -27.16% |
| 2015-06-30 | $64.75 Million | +30.00% |
| 2014-06-30 | $49.81 Million | +36.28% |
| 2013-06-30 | $36.55 Million | +473.47% |
| 2012-06-30 | $6.37 Million | +52.90% |
| 2011-06-30 | $4.17 Million | -54.38% |
| 2010-06-30 | $9.14 Million | -52.80% |
| 2009-06-30 | $19.36 Million | -3.11% |
| 2008-06-30 | $19.98 Million | +22.64% |
| 2007-06-30 | $16.29 Million | +56.71% |
| 2006-06-30 | $10.39 Million | -46.32% |
| 2005-06-30 | $19.36 Million | -22.07% |
| 2004-06-30 | $24.85 Million | +241.05% |
| 2003-06-30 | $7.29 Million | -20.68% |
| 2002-06-30 | $9.19 Million | -- |
About MEI Pharma Inc
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, … Read more